切换至 "中华医学电子期刊资源库"

中华临床实验室管理电子杂志 ›› 2016, Vol. 04 ›› Issue (01) : 13 -17. doi: 10.3877/cma.j.jssn.2095-5820.2016.01.004

所属专题: 文献

综述

肿瘤靶向药物相关受体研究进展
胡敏1,(), 王继贵1   
  1. 1. 410011 长沙,中南大学湘雅二医院检验科
  • 收稿日期:2015-10-22 出版日期:2016-02-28
  • 通信作者: 胡敏

Investigating progress on targeted anticancer therapy

Min Hu1,(), Jigui Wang1   

  1. 1. Department of Clinical Laboratory, the Second Xiangya Hospital of Central South University, Changsha 410011, China
  • Received:2015-10-22 Published:2016-02-28
  • Corresponding author: Min Hu
  • About author:
    Corresponding author: Hu Min, Email:
引用本文:

胡敏, 王继贵. 肿瘤靶向药物相关受体研究进展[J]. 中华临床实验室管理电子杂志, 2016, 04(01): 13-17.

Min Hu, Jigui Wang. Investigating progress on targeted anticancer therapy[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2016, 04(01): 13-17.

对癌细胞及其组织靶向给予抗癌药物是临床治疗癌症的新手段,当细胞毒化疗剂(如紫杉醇和阿霉素)有效杀死癌细胞时,它们并不能区分癌细胞和正常细胞;当患者需要根除肿瘤大剂量使用细胞毒剂药物时,这种非针对性的特异性选择将导致患者全身毒性不良反应,从而造成患者非肿瘤部位组织和功能损伤。本文主要针对靶向药物在肿瘤微环境过表达受体的作用机制,及7种相关受体分子的结构和功能特点进行阐述。

Targeted delivery of anticancer drugs to cancer cells and tissues is a promising field. While cytotoxic chemotherapeutic agents such as paelitaxel and doxorubicin effectively kill cancer cells, they cannot distinguish cancer cells from normal cells, the lack of selectivity will cause systematic toxicity to patients when they are exposed to the high dosages of cytotoxic agents required to eradicate the tumor. This article focuses on overexpressed receptors exploited for targeting drugs to cancer and the tumor microenvironment, and briefly evaluates the structure and function of these receptor molecules.

1
Sutcliffe SB. Cancer control:life and death in an unegual world [J]. Curr Oncol, 2012,19(1):12-15.
2
Zwanziger D, Beck-Sickinger AG. Radiometal targeted tumour diagnosis and therapy with peptide hormones [J]. Curr Pharm Des, 2008,14(24):2385-2400.
3
Sancho V, Di Florio A, Moody TW, et al. Bombesin receptor mediated imaging and cytotoxicity:review and current status[J]. Curr Drug Deliv, 2011,8(1):79-134.
4
Majumdar ID, Weber HC. Biology of mammalian bombesin-like peptides and their receptors [J]. Curr Opin Endocrinol Diabetes Obes, 2011,18(1):68-74.
5
Sun LC, Coy DH. Somatostatim receptor-targeted anti-cancer therapy[J]. Curr Drug Deliv, 2011,8(1):2-10.
6
Asundi J, Reed C, Arca J, et al. An antibody-drug conjugate targeting the endothelin B receptor for the tretment of melanoma [J]. Clin Cancer Res, 2011,17(5):965-975.
7
Desrosellier JS, Cheresh DA. Integrins in cancer:biological implications and therapeutic opportunities [J]. Nat Rev Cancer, 2010, 10(1):9-22.
8
zhan C, Gu B, Xie C, et al. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid)micell enhances paclitaxel anti-glioblastoma effect [J]. J Control Release, 2010,143(1):136-142.
9
Xiao K, Li Y, Lee JS, et al. OA02 peptide facilitates the precise targetimg of pacitaxel-loaded micellar nanoparticles to ovarian in vivo [J]. Cancer Res, 2012, 72(8):2100-2110.
10
Chen C, Ke J, Zhou XE, et al. Structural basis for molecular recognition of folic acid by folate receptors [J]. Nature, 2013,500(7463):486-489.
11
Muller C, Schibli R. Folic acid conjugates for nuclear imaging of folate receptor positive cancer [J]. J Nucl Med, 2011,52(1):1-4.
12
Liu X, Ma S, Dai C, et al. Antiprolifeative, antiinvasive,and proapoptotic activity of folate receptor α-targeted liposomal DOX in nonfunctional pituitary adenoma cells [J]. Endocrinology, 2013,154(4):1414-1423.
13
Dufes C, AI Robaian M, Somani C. Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells [J]. Ther Deliv, 2013,4(5):629-640.
14
Han CY, Yue LL, Tai LY, et al. A novel small peptide as an epidermal growth factor receptor targeting ligand for nanodelivery in vitro [J]. Int J Nanomedicine, 2013,8:1541-1549.
15
Xiao W, Chen X, Yang L, et al. co-delivery of DOX and plasmid by a novel FGFR-mediated cationic liposome [J]. Int J Pharm, 2010,393(1-2):119-126.
16
Spitzer D, Simon PO Jr, Kashiwagi H, et al. Use of multifunctionakl sigma-2 receptor ligand conjugated to trigger cancer selective cell death signaling [J]. Cancer Res, 2012,72(1):201-209.
[1] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[2] 马敏榕, 李聪, 周勤. 宫颈癌治疗研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 497-504.
[3] 林昌盛, 战军, 肖雪. 上皮性卵巢癌患者诊疗中基因检测及分子靶向药物治疗[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 505-510.
[4] 王璐, 樊杨. 子宫内膜癌相关生物标志物研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 511-516.
[5] 王得晨, 杨康, 杨自杰, 归明彬, 屈莲平, 张小凤, 高峰. 结直肠癌微卫星稳定状态和程序性死亡、吲哚胺2,3-双加氧酶关系的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 462-465.
[6] 闫甲, 刘双池, 王政宇. 胆囊癌肿瘤标志物的研究和应用进展[J]. 中华普通外科学文献(电子版), 2023, 17(05): 391-394.
[7] 冯冰, 邹秋果, 梁振波, 卢艳明, 曾奕, 吴淑苗. 老年非特殊型浸润性乳腺癌超声征象与分子生物学指标的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 48-51.
[8] 曹长青, 郭新艳, 高源, 张存, 唐海利, 樊东, 杨小军, 张松, 赵华栋. 肿瘤微环境参与介导HER2阳性乳腺癌曲妥珠单抗耐药的研究进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 90-95.
[9] 张圣平, 邓琼, 张颖, 张建文, 梁辉, 王铸. 孤儿核受体HNF4α在肾透明细胞癌中的表达及意义[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 627-632.
[10] 魏小勇. 原发性肝癌转化治疗焦点问题探讨[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 602-607.
[11] 吴晨瑞, 廖锐, 贺强, 潘龙, 黄平, 曹洪祥, 赵益, 王永琛, 黄俊杰, 孙睿锐. MDT模式下肝动脉灌注化疗联合免疫靶向治疗肝细胞癌多处转移一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 713-716.
[12] 王淑友, 宋晓晶, 贾术永, 王广军, 张维波. 肝脏去唾液酸糖蛋白受体靶向活体荧光成像评估酒精性肝损伤肝脏功能的研究[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 443-446.
[13] 曹旬旬, 费素娟. 食管癌患者肿瘤组织CXCL5和CXCR2的表达与病情和预后的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 299-304.
[14] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
[15] 符梅沙, 周玉华, 李慧, 薛春颜. 淋巴细胞免疫治疗对复发性流产患者外周血T淋巴细胞亚群分布与PD1/PD-L1表达的影响及意义[J]. 中华临床医师杂志(电子版), 2023, 17(06): 726-730.
阅读次数
全文


摘要